Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Azienda Sanitaria Provinciale Di Catanzaro | OTHER |
Not provided
Not provided
Not provided
Not provided
Microbiota consists of trillions of microorganisms located in all the biological cavity. The relationships between individual health status and microbiota are based on a sort of "mutual cooperation." The balance of the microbiota can be compromised by various factors such as environmental, psycho-physical stress, malnutrition (over or low), breastfeeding, chronic diseases, oncology and pharmacological treatments (especially antibiotics and chemotherapics). The impact of dysbiosis on today's society affects over 70% of the world population
Intestinal microbiota is defined as the strongest modulator of the human genome and it is considered the "second brain" of our organism for its bi-directional communication with the central nervous system. Microbiota consists of trillions of microorganisms located in all the biological cavity, In the intestine it is distributed in ecological niches having multiple metabolic activities which influence individual health. Microbiota acts as barrier against pathogens, regulating the absorption of nutrients, the production of energy and the development of the immune system4. Intestinal bacteria are generally divided into 4 Phylum: Firmicutes, Actinobacteria, Proteobacteria and Bacteriodetes, in which their proportion shows a correlation with individuals health status. When in equilibrium among them, these bacteria are essential for the good health of the digestive tract, the good function of immune system and for brain performace. The relationships between individual health status and microbiota are based on a sort of "mutual cooperation." The balance of the microbiota can be compromised by various factors such as environmental, psycho-physical stress, malnutrition (over or low), breastfeeding, chronic diseases, oncology and pharmacological treatments (especially antibiotics and chemotherapics). This disequilibrium leads to altered capability of bacteria to properly extract calories from food affecting the trend of many pathophisilogical status such as obesity, allergic states, inflammatory bowel syndromes cardiovascular diseases, metabolic, oncological and neurodegenerative diseases. The impact of dysbiosis on today's society affects over 70% of the world population
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Healthy people of both sex |
| |
| quantification of microbiota in Brain | Patients of both sex with neural disorders and diseases |
| |
| quantification of microbiota in GI | Patients of both sex with gastrointestinal diseases |
| |
| quantification of microbiota in Lung | Patients of both sex with Respiratory diseases |
| |
| quantification of microbiota Metabolic | Patients of both sex with Metabolic Diseases |
| |
| quantification of microbiota in UG | Patients of both sex with Uro-genital Diseases |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| quantification of microbiota | Diagnostic Test | For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis |
| Measure | Description | Time Frame |
|---|---|---|
| Determination of microbiota percentage | we will determine the difference of microbiota percentage in diseases-groups respect to control-group | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Determination of antibiotic resistance gene | it will be evaluate the presence of antibiotic resistance gene in diseases-group respect to control-group | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Health and disease patients, after a detailed history will be enrolled in one of the six groups and a biological sample will be take for the examination using the n-counter platform.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Luca Gallelli, MD | Contact | +390961712322 | gallelli@unicz.it |
| Name | Affiliation | Role |
|---|---|---|
| Luca Gallelli, MD | University of Catanzaro | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AO Materdomini | Recruiting | Catanzaro | Italia | 88100 | Italy |
data will kept in hospital and results will be published
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D004194 | Disease |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided